Fox Business - The Power to Prosper
Search Site

Schering-Plough

Merck CEO on aiding the fight against maternal mortality

Merck CEO Ken Frazier on his company’s efforts to prevent maternal mortality.

Read More

  1. Merck : FDA Extends Review of Sugammadex by 3 Months

    Merck & Co. (MRK) said the U.S. Food and Drug Administration has extended by three months its review of the company's application to market a new postsurgical drug.M...

  2. Long-serving Roche chairman to step down next year

    Roche's influential Chairman Franz Humer said on Tuesday he will not stand for re-election next year when he will have served 16 years at the helm, potentially accel...

  3. Bausch & Lomb Names Robert Bertolini as New Financial Chief

    Contact lens maker Bausch & Lomb Inc. has named Robert Bertolini as its new chief financial officer effective immediately, replacing Brian J. Harris."Bob Bertolini's...

  4. Merck to Pay $688 Million to Settle Drug Study Suits

    Merck & Co. (MRK) agreed to pay $688 million to settle lawsuits claiming that shareholders lost money when the company reported negative results of a clinical trial ...

  5. Merck Pays $688M to Settle Investor Suit

    Merck (NYSE:MRK) agreed to pay $688 million on Thursday to settle two federal securities class-action lawsuits filed by Merck investors who claimed they lost money w...

  6. Merck to Pay $688 Million to Settle 'Enhance' Trial Lawsuits

    Merck & Co. (MRK) will pay $688 million to settle two federal securities class-action lawsuits brought by investors who bought certain Merck and Schering-Plough Corp...

  7. Al's Emporium: Calling Dr. Schwag

    A few doctors didn't appreciate a comment I made in last week's column that pharmaceutical-industry reps unduly influence medical decisions by plying physicians with...

  8. FDA Denies Merck Request to Block Generic Form of Nasonex

    Merck & Co. (MRK) lost another round in its effort to block a competing generic copy of its Nasonex allergy nasal spray from entering the U.S. market.The U.S. Food a...

  9. India Revokes Patent on Merck Asthma Drug -Reuters

    Citing lack of invention, India has revoked a patent on an asthma drug made by Schering Corp., which was later bought by Merck & Co. (MRK), Reuters reported Tuesday....

  10. America's Most Valuable CEOs

    There is a nearly endless number of criteria that measure how well CEOs perform, whether they are paid fairly, and what metrics should be used for determining chief ...

  11. Merck to Move Global Headquarters to Summit NJ in Push to Cut Costs

    Merck & Co. (MRK) will move its global headquarters to an existing property in Summit, N.J., from Whitehouse Station, N.J. as the drug giant continues its cost-cutti...

  12. Avon Chairman Andrea Jung to Resign

    Avon Products Inc. (AVP) said Chairman Andrea Jung will step down at the end of the year and will be succeeded by Fred Hassan.Ms. Jung will continue as a senior advi...

  1. Inside Merck with CEO Ken Frazier

    Merck CEO Ken Frazier, in a wide-ranging interview, weighs in on the consumer business and what’s in the pipeline.

  2. Merck Snags Baxter Executive As CFO

    Merck (NYSE:MRK) tapped Baxter (NYSE:BAX) executive Robert Davis on Thursday to replace current finance head Peter Kellogg as the company struggles to revive sales a...

  3. Forest Labs Plans To Buy Schizophrenia Drug, Cut Costs

    Forest Laboratories Inc, which is facing patent expirations on several of its biggest drugs, on Monday said it planned to buy rights to a new schizophrenia drug from...

  4. Ex-Chairman of Avon: Know When it's Time for CEO to Go

    Fred Hassan, author of ‘Reinvent: A Leader’s Playbook for Serial Success,’ shares his secrets to growth and enhancing company culture.

  5. Avon Chairman Hassan Resigns from Board

    Avon Products Inc. (AVP) said Chairman Fred Hassan, known in the industry as a savvy deal maker, has resigned from the board, just months after taking the chairman p...

  6. Some Drug Makers Cut Payments, Meals Provided to Doctors

    Two pharmaceutical companies that are among the biggest payers of fees to doctors reduced such spending last year by double-digit percentages, as greater transparenc...

  7. Top Court to Decide on Deals to Delay Cheaper Drugs

    The U.S. Supreme Court will hear arguments on Monday over whether big drug companies can settle patent litigation with generic rivals by making deals to keep cheaper...

‹ Prev123Next ›
Freebase CC-BY
Source: Schering-Plough on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL